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Abstract 
Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin’s lymphomas 
(NHL). DLBCL is an aggressive malignancy that displays a great heterogeneity in terms of morphology, genetics 
and biological behavior. While a sustained complete remission is obtained in the majority of patients with standard 
immunochemotherapy, patients with refractory of relapsed disease after first-line treatment have a poor prognosis. 
This patient group represents an important unmet need in lymphoma treatment. In recent years, improved under-
standing of the underlying molecular pathogenesis had led to new classification and prognostication tools, includ-
ing the development of cell-free biomarkers in liquid biopsies. Although the majority of studies have focused on 
the use of cell-free fragments of DNA (cfDNA), there has been an increased interest in circulating-free coding and 
non-coding RNA, including messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA) and circular 
RNA (circRNA), as well as RNA encapsulated in extracellular vesicles or tumor-educated platelets (TEPs). We performed 
a systematic search in PubMed to identify articles that evaluated circulating RNA as diagnostic, subtype, treatment 
response or prognostic biomarkers in a human DLBCL population. A total of 35 articles met the inclusion criteria. The 
aim of this systematic review is to present the current understanding of circulating RNA molecules as biomarker in 
DLBCL and to discuss their future potential.
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Introduction
A lymphoma is a hematopoietic malignancy that devel-
ops in the lymphoid tissue. The diffuse large-cell B-cell 
lymphoma (DLBCL) is the most common histological 
subtype of non-Hodgkin’s lymphomas (NHL), represent-
ing approximately 25% of new diagnoses. It can occur de 
novo or as a result of transformation from different types 
of low-grade B-cell lymphomas such as chronic lymphatic 
leukemia (CLL), lymphoplasmocytic lymphoma, folli-
cular lymphoma and (splenic) marginal zone lymphoma. 
With the standard treatment of R-CHOP immunochem-
otherapy (rituximab, cyclophosphamide, vincristine, 
doxorubicin and prednisone), sustained remission can 
be obtained in approximately 60–70% of patients  [1]. 
However, patients with refractory or relapsed disease 
after first-line treatment have a reserved prognosis with 
a 5-year survival rate of only 20%, despite second-line 
treatments [2, 3]. This subgroup represents an important 
unmet need in lymphoma treatment. The prognostic dif-
ferences in terms of response and survival reflect the het-
erogeneity of different subgroups of DLBCL with respect 
to morphology, genetics and biological behavior.
A liquid biopsy is the process of investigating tumor-
derived cells or biomaterials like cell-free nucleic acids, 
metabolites, proteins or extracellular vesicles through 
biofluid sampling such as peripheral blood, urine, saliva, 
and cerebral spinal fluid, without the need of a tissue 
biopsy. In recent years, there has been a major inter-
est and advance in the use of liquid biopsy in lymphoma 
management due to its non-invasive nature, its ability to 
reflect spatial inter- and intra-tumor heterogeneity, and 
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the possibility of repeated measurements through longi-
tudinal profiling [4].
 The vast majority of studies have focused on the use 
of circulating cell-free DNA fragments (cfDNA), a pro-
portion of which is derived from lymphoma cells (cir-
culating tumor DNA; ctDNA). Studies have shown 
that cfDNA plasma concentration is associated with 
lymphoma aggressiveness, tumor volume and disease 
stage, may predict therapy response, and has prognos-
tic value in assessing progressive, relapsing or minimal 
residual disease. Moreover, cfDNA is able to represent 
the clonality and mutational burden of DLBCL and can 
discriminate between different cell-of-origin (COO) sub-
groups: germinal center B-cell-like (GCB) and activated 
B-cell-like (ABC) [4–6]. The COO classification is origi-
nally based on gene expression profiling and is routinely 
implemented through the use of surrogate immunohis-
tochemical techniques, such as the Hans algorithm  [7, 
8]. Scherer et  al. showed a 80% concordance rate with 
the Hans algorithm using the identification of mutations 
obtained through liquid biopsies [5]. Several studies have 
formulated other DLBCL classifications with prognostic 
implications, based on different mutations and structural 
variations found in tissue biopsies, one of which could 
already be reproduced using ctDNA with high concord-
ance [9–15]. These classifications may complement con-
ventional prognostic scores, such as the international 
prognostic index (IPI), in identifying high-risk subsets of 
patients  [16]. The importance of understanding the het-
erogeneity in DLBCL was illustrated by several studies 
that identified subgroups of high-risk patients that could 
benefit from associating targeted therapy to standard 
treatment, emphasizing the significance of a personalized 
medicine approach [17–19].
 In recent years, there has been an increased interest in 
other circulating biomarkers, such as circulating tumor 
cells (CTC) and different forms of circulating-free and 
extracellular vesicle/platelet-encapsulated coding and 
non-coding RNA, including messenger RNA (mRNA), 
microRNA (miRNA), long non-coding RNA (lncRNA), 
and circular RNA (circRNA) (Fig.  1). Although CTC 
may provide tumor-specific genomic, transcriptomic, 
and proteomic information, their analysis is less attrac-
tive since DLBCL do not typically present with circulat-
ing lymphoma cells (in contrast to mantle cell lymphoma, 
follicular lymphoma (FL), marginal zone lymphoma, 
extracellular vesicle


















Fig. 1 Circulating biomarkers in DBLCL. A schematic representation of circulating biomarkers obtained through blood draw, such as circulating 
tumor cells (CTC), tumor-educated platelets (TEPs), cell-free DNA(cfDNA) and cell-free RNA (cfRNA). a Extracellular vesicles include exosomes, 
microvesicles and apoptotic bodies. Their cargo reflects the cell of origin and contains proteins, peptides, lipids, cfDNA and cfRNA.b CfRNA 
comprises both coding and non-coding types, including mRNA, miRNA, lncRNA and circRNA. c Figure produced using Servier Medical Art
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small lymphocytic lymphoma, and a subset of Burkitt 
lymphoma) [20]. Also, CTC analysis requires a large vol-
ume of fresh blood, and is laborious and expensive. The 
use of cell-free RNA (cfRNA), however, has shown prom-
ise as a precision medicine biomarker. Here, we provide 
a systematic overview of cell-free RNA biomarkers in 
DLBCL and their future potential in the diagnosis, clas-
sification, real-time measurement of response to therapy, 
and prognosis.
Materials and methods
 A systematic search in PubMed was performed to iden-
tify articles published between January 01, 1970 and 
October 31, 2020 using the following strategy (Fig.  2): 
[(DLBCL OR “Diffuse Large B-Cell Lymphoma”) AND 
(“liquid biopsy”) OR (DLBCL OR “Diffuse Large B-Cell 
Lymphoma”) AND (exosome OR “extracellular vesicles” 
OR secretome) OR (DLBCL OR “Diffuse Large B-Cell 
Lymphoma”) AND ((“messenger RNA” OR mRNA) OR 
(microRNA OR miRNA or miR) OR (“long non-coding 
RNA” OR lncRNA) OR (“circular RNA” OR circRNA)) 
AND (circulating OR “peripheral blood” OR “cell-free” 
OR free OR plasma OR serum) OR (DLBCL OR “Dif-
fuse Large B-Cell Lymphoma”) AND ((circulating OR 
“peripheral blood”) AND RNA)]. Articles were included 
if they presented independent original studies in a human 
adult DLBCL population. Reviews and meta-analyses, 
case reports, letters, comments, and articles not pub-
lished in English were excluded. We also excluded studies 
on animals, DLBCL cell lines/xenografts, as well as stud-
ies that did not analyze RNA or did not focus on primary 
DLBCL. After full text assessment, articles investigat-
ing patients with additional pathologies or not analyz-
ing circulating RNAs as biomarker in diagnosis, subtype 
classification, treatment response, or prognosis, were 
(DLBCL OR "Diffuse Large 
B-Cell Lymphoma") AND 
((circulang OR 
“peripheral blood”) AND 
RNA) 
(n=73)
(DLBCL OR "Diffuse Large 
B-Cell Lymphoma") AND 
("liquid biopsy") 
(n=27)
(DLBCL OR "Diffuse Large 





(DLBCL OR "Diffuse Large B-Cell Lymphoma”) AND 
((“messenger RNA” OR mRNA) OR (microRNA OR miRNA or 
miR) OR (“long non-coding RNA” OR lncRNA) OR (“circular 
RNA” OR circRNA)) AND (circulang OR “peripheral blood” 
OR “cell-free” OR free OR plasma OR serum) 
(n=235)
records (n=360)
full text arcles assessed for eligibility (n=101)
Duplicates removed (n=70)
records (n=290)
arcles added aer checking references (n=3) 
full text arcles excluded (n=69):
- in EBV+/HIV+ paents (n=5)




- case report (n=3)
- leer/comment (n=2)
- arcle not in English (n=14)
- non-human study/cell line (n=40)
- no RNA study (n=53)













Fig. 2 Flowchart of study selection
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excluded. All references within the selected studies were 
reviewed in order to identify additional matches.
Each eligible manuscript was assessed independently 
by two researchers. Disagreements were resolved by con-
sensus. Data extracted from each study included: publica-
tion year, technical methodology and type of blood-based 
fluid analyzed, method of EV purification, number of 
DLBCL cases and controls, the investigated RNAs as 
potential biomarkers, and their association with an out-
come. In order to define associations between the abun-
dance of the RNAs and the phenotypes, a p-value < 0.05 
was considered statistically significant.
Results
A total of 360 records were initially identified and 290 
remained after removing duplicates. Among these, 189 
were excluded after abstract revision because they did not 
meet the inclusion criteria. Based on the full text of 101 
articles, 69 articles were excluded because they focused 
on tissue-derived RNA or on specific patient groups with 
additional pathologies. After reviewing the references 
of the identified articles, three additional studies were 
included. Finally, a total of 35 articles were included and 
classified into the following groups, depending on the 
type of circulating RNA studied: mRNA, miRNA, EV, 
lncRNA, circRNA, and tumor-educated platelets (TEPs) 
(Fig. 2).
Cell‐free RNA
Although 80% of the human genome is transcribed into 
RNA, it has been estimated that protein-coding mRNA 
only accounts for 1.5% of this output with the remain-
der being termed non-coding RNA (ncRNA) [21]. As the 
functions of most ncRNA remain largely unknown, cur-
rent classifications are based primarily on size and differ-
entiate between short ncRNAs (less than 200 nucleotides, 
including miRNAs) and large ncRNAs (larger than 200 
bases, generally termed lncRNAs, but also including 
circRNAs) [22].
Circulating-free RNAs are unstable molecules that 
are quickly degraded by ribonucleases. This was dem-
onstrated in a lability experiment, in which 99% of 
added naked RNA was degraded after a 15 s incubation 
time  [23]. It is clear that endogenous circulating RNAs 
are protected by several mechanisms, such as encap-
sulation within extracellular vesicles (EVs) or they form 
ribonucleoprotein complexes with RNA-binding pro-
teins such as nucleophosmin, high-density lipoprotein 
or Argonaute 1 and 2 that protect them from nuclease 
activity. Although the source and function of circulating 
RNAs are largely unclarified, RNAs seem to be selectively 
packaged according to the viability and origin of the cells. 
While living cells actively release RNA encapsulated 
in large lipoprotein complexes, such as exosomes or 
microvesicles (MVs), RNA from dead or dying cells found 
in blood is associated with apoptotic bodies (ABs) or pro-
tein complexes  [24–26]. Lastly, circulating RNA can be 
encapsulated by platelets that, when exposed to tumor 
cells, can be ‘educated’ by changing their RNA profile, 
mainly by altering splicing patterns and to lesser extent 
by ingestion of tumor-derived circulating RNA and EVs. 
These platelets are referred to as tumor-educated plate-
lets (TEPs) [27–31].
Higher circulating RNA levels have been found in 
patients with solid and hematological malignancies, com-
pared to patients without tumor. It is believed that can-
cer cells communicate with surrounding stromal and 
immune cells via extracellular RNAs, which may con-
tribute to increased proliferation, malignant transfor-
mation of surrounding cells, angiogenesis, escape from 
the immune response, and priming of future metastatic 
niches [25, 26, 32]. Although being technically more chal-
lenging than cfDNA, the analysis of cfRNA may therefore 
have certain advantages as biomarker. Since these mol-
ecules mediate or influence intercellular communica-
tion, they may lead to an improved understanding of key 
pathways involved in normal differentiation, as well as in 
lymphoma initiation and transformation. Moreover, dif-
ferences in cfRNA patterns may reflect functional, longi-
tudinal changes in both the tumor and the non-malignant 
compartment during disease course or treatment. This 
specific and dynamic characterization, which incorpo-
rates the crosstalk between tumor and environment, may 
guide the development of individualized diagnostic and 
therapeutic options, especially in genetically heterogene-
ous diseases such as DLBCL.
Up to this date, we found 35 studies that have examined 
the serum/plasma levels of RNA and its association with 
clinical and pathological characteristics of DLBCL, sug-
gesting that cell-free RNA may provide biomarkers for 
the diagnosis, classification, measurement of response to 
therapy, and prognosis.
Messenger RNA
Messenger RNA (mRNA) is the result of DNA transcrip-
tion and possesses a critical intermediary role in intracel-
lular protein translation, reflecting both the genomic and 
the homeostatic state of the cell. These properties make 
mRNA a potentially interesting target for liquid biopsy. 
In 1991, Smith et  al. used PCR analysis on tyrosinase 
mRNA, a tissue-specific gene in melanocytes, to detect 
the presence of circulating melanoma cells [33]. This was 
followed by the identification of tyrosinase mRNA in the 
serum of melanoma patients  [34]. Over the years, cir-
culating tumor mRNAs haven been described in many 
different tumors and their levels were associated with 
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cancer aggressiveness, disease prognosis and response 
to chemoradiotherapy  [35–39]. Moreover, they have 
shown potential to guide individualized therapy choice, 
as was illustrated by the detection of different ALK fusion 
mRNAs with high sensitivity and specificity in patients 
with non-small cell lung cancer [40].
Four studies have investigated cell-free mRNAs in 
DLBCL (Table  1). Garcia et  al. showed that G1/S-spe-
cific cyclin-D2 (CCND2), MYC proto-oncogene protein 
(MYC), B-cell lymphoma 2 (BCL2), and LIM domain 
only 2 (LMO2) mRNAs were significantly higher in 
DLBCL plasma samples. The presence of circulating 
MYC or CCND2 mRNA was associated with worse over-
all survival (OS), especially in low-risk IPI group, and the 
presence of CCND2, BCL2 or MYC mRNA in patients 
with complete response (CR) was associated with worse 
progression-free survival (PFS)  [41]. These genes are 
known to play important roles in lymphomagenesis. 
CCND2 is a key player in cell division and proliferation, 
regulated by the phosphatidylinositol 3/kinase-protein 
kinase B/mammalian target of rapamycin (PI3K/AKT/
mTOR) pathway. The MYC gene encodes for a transcrip-
tion factor that controls numerous biological functions, 
including proliferation, cell growth, telomerase activ-
ity, energy metabolism, differentiation, and apoptosis, 
as well as DNA replication. BCL2 is a key anti-apoptotic 
molecule expressed in most tissues but absent in the ger-
minal center, and LMO2 is expressed in all tissues with 
the exception of mature T-cells and is implicated in angi-
ogenesis, hematopoiesis, and hematopoietic stem cell 
maintenance [42, 43]. Zhao et al. demonstrated a higher 
abundance of CREBBP mRNA in DLBCL blood sam-
ples as compared with controls. However, no differences 
were found in OS and PFS. CREBBP is one of the most 
frequently mutated genes in DLBCL and acts as a tumor 
suppressor of germinal center-derived lymphomagenesis 
by promoting transcription, counteracting the inhibition 
of B-cell lymphoma 6 (BCL6) [44]. Attia et al. showed that 
a higher abundance of suppressor of cytokine signaling 
3 (SOCS-3) mRNA in plasma samples of NHL patients 
correlates with advanced disease and poor response to 
treatment. However, no separate analysis of the DLBCL 
patient subgroup has been performed, limiting its inter-
pretation. SOCS3, among other functions, inhibits the 
Janus kinase (JAK)-signal transducer and activator of 
transcription (STAT) signaling, known to be involved in 
DLBLC [18, 45, 46]. Lastly, Ujj et al. showed that higher 
levels of the Wilms tumor 1 (WT1) mRNA were asso-
ciated with worse disease-free survival (DFS) and OS. 
WT1 is a DNA-binding protein with a complex function 
Table 1 Cell-free mRNA in DLBCL
CR complete response, DFS disease-free survival, IPI international prognostic index, mRNA messenger RNA, NHL non-Hodgkin’s lymphoma, NR no response, NS not 
significant, OS overall survival, PFS progression-free survival, PR partial response, RT-qPCR reverse-transcription quantitative polymerase chain reaction
References Method Sample mRNA Level Result
Diagnosis
Garcia et al. [41] RT-qPCR plasma 42 DLBCL
50 controls




Higher level in DLBCL
No difference
Zhao et al.[44] RT-qPCR peripheral blood 63 DLBCL
32 controls
CREBBP Up Higher level in DLBCL
Response to therapy
Garcia et al. [41] RT-qPCR plasma 42 DLBCL
50 controls
MYC
CCND2, BCL2, LMO2, BCL6,FN1
Up
NS
Higher level of MYC was associated 
with PR in patients with low-risk 
IPI
No significant association with 
response to R-CHOP
Attia et al. [45] RT-qPCR plasma 30 NHL (15 DLBCL)
20 controls
SOCS-3 Up Higher level was associated with 
poor response to treatment (NR/
PR versus CR) in NHL
Prognosis






Higher level of MYC or CCND2 
was associated with worse OS, 
with the latter only in low-risk IPI 
group
Higher level of CCND2, BCL2 or 
MYC in patients with CR was 
associated with worse PFS




WT1 Up Higher level in pre-, intra- or post-
treatment samples was associ-
ated with worse DFS and OS
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due to its many isoforms. Although WT1 is known to act 
as a tumor suppressor in Wilms tumor, it seems to be an 
oncogene in other neoplasms [47].
The number of studies that have investigated cell-free 
mRNA is limited and the sample sizes are small. More-
over, none of the mRNAs have been studied by two or 
more different studies. Therefore, no well-founded con-
clusion can be made of their potential use and more 
studies are needed to validate these results. Compared 
to other types of RNA, research of circulating mRNA is 
challenging due to its relatively low abundance, as well as 
intracellular mRNA contamination and susceptibility to 
degradation  [23, 48]. Despite these challenges, cell-free 
mRNAs may provide valuable insight in critical intracel-
lular processes, both in tumor cells and in the cancer-
associated microenvironment, as they possess a critical 
role in protein translation.
MicroRNA
MicroRNAs (miRNAs) are short non-coding RNAs of 
∼ 22 nucleotides, which are found in all eukaryotic cells. 
MiRNAs play pivotal roles in almost all biological path-
ways, regulating gene expression by targeting mRNA at 
the 3′-untranslated region  [49, 50]. Since miRNAs can 
target up to several hundred mRNAs, aberrant expres-
sion can influence a multitude of cell signaling pathways, 
including cancer onset and progression. Contrary to 
mRNAs, miRNAs are resistant to ribonuclease digestion 
due to their small size and remain stable after being sub-
jected to harsh conditions under which most other RNA 
would degrade  [51]. Furthermore, studies have revealed 
genetic exchange between cells using miRNA in extracel-
lular vesicles, such as exomes  [26, 52]. MiRNAs are the 
most widely investigated subgroup of non-coding RNA in 
DLBCL. The first study investigating circulating miRNA 
in DLBCL was reported in 2008 by Lawrie et  al., who 
demonstrated that serum levels of miR-21 were higher 
in DLBCL and were associated with relapse‐free survival 
(RFS) [53]. Since then, several cell-free miRNA have been 
proposed as biomarker [53] (Table 2).
As diagnostic biomarkers in DLBCL, a total of eight 
different miRNAs (miR-15a, miR-21, miR-29c, miR-34a, 
miR-145, miR-155, miR-210, and miR-375) were found 
to be significantly dysregulated in at least two differ-
ent studies. The studies concerning miR-145, miR-375, 
miR-15a, miR-21 and miR-155 presented the most con-
cordant results, the first two miRNAs being lower and 
the following three being higher in DLBCL [53, 55–65]. 
MiR-145 and miR-375 were lower in two studies and are 
considered tumor suppressors in different cancer types. 
MiR-145 targets among others the oncogenes MYC and 
protein C-ets-1 (ETS1), and miR-375 targets the astro-
cyte elevated gene 1 (AEG-1), yes-associated protein 1 
(YAP1), insulin like growth factor 1 (IGF1R) and pyru-
vate dehydrogenase kinase isoenzyme 1 (PDK1)  [58, 
63, 66–68]. MiR-15a was higher in three different stud-
ies  [55, 64, 69]. Although being described as a tumor 
suppressor in CLL by targeting BCL-2, miR-15a has 
also been shown to target p53 in a miRNA/p53 feed-
back circuitry. Its higher abundance and role in DLBCL, 
however, remain unclear  [70–72]. MiR-21 was higher in 
eight out of nine studies and one study showed no sig-
nificant change. MiR-21 is considered to be an oncomiR 
that can be transcriptionally activated by nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-
κB) and downregulates different phosphatases, such as 
programmed cell death protein 4 (PDCD4) and phos-
phatase and tensin homolog (PTEN), which are major 
players in crucial signaling pathways such as PI3K/AKT 
and mitogen-activated protein kinase (MAPK)  [53, 55, 
57–59, 61, 64–66]. Although its physiological function 
during normal B-cell development remains unclear, miR-
21  is upregulated in GC and memory B cells compared 
to naive B cells and downregulated in plasma cells, which 
suggests a functional significance during differentiation. 
The decreased expression in plasma cells correlates with 
increasing B lymphocyte-induced maturation protein-1 
(BLIMP-1) expression, the regulator of plasma cell dif-
ferentiation [73, 74]. A mouse model demonstrated that 
miR-21 overexpression led to a pre-B malignant lym-
phoid-like phenotype and impacted the different stages 
of tumor development in  vivo. Subsequent inactivation 
led to complete tumor regression mediated by increased 
apoptosis and proliferative arrest. This dependence may 
suggest an ‘oncogene addiction’ and therefore therapeu-
tic potential of miR-21 inhibition [75]. Moreover, a posi-
tive feedback loop of sustained miR-21 upregulation and 
NF-κB activation has been demonstrated in non-DLBCL 
cancer cell lines, triggered by an inflammatory response 
and supporting oncogenic transformation  [76]. These 
results warrant further exploration of miR-21 in DLBCL. 
MiR-155 was higher in six out of ten studies and four 
studies showed no significant change. MiR-155  is gen-
erally known as an oncomiR in many different tumors, 
targeting genes that play a central role in lymphomagen-
esis, such as suppressor of cytokine signaling (SOCS), 
phosphatidylinositol 3-kinase regulatory subunit alpha 
(PIK3R1) and src homology 2-domain-containing ino-
sitol 5′-phosphatase 1 (SHIP1)  [53, 55, 58, 60, 64–66, 
69, 77–79]. Lastly, Beheshti et  al. combined five miR-
NAs in a signature that was able to differentiate DLBCL 
patients from healthy controls with a classification rate 
of 91% [69].  To this date, miR-155 and especially miR-
21 seem to show the most promising potential as diag-
nostic biomarker. These findings are in line with a recent 
systematic review regarding miRNA analysis on tissue 
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specimens  [77]. Interestingly, dysregulation of cell-free 
miRNAs may precede the diagnosis up to 2 years, high-
lighting their potential as early biomarkers, before the 
onset of clinical symptoms [66].
For DLBCL subclassification, no miRNA was found 
to be significantly dysregulated in at least two differ-
ent studies. MiR-21 and miR-155 expression levels were 
higher in the ABC subgroup in two smaller studies  [59, 
79]. Since these observations have not been validated, 
their use as biomarker remains uncertain. On tissue 
specimens, the most consistent results were obtained for 
miR-155-5p and miR-221-3p, which were upregulated in 
the ABC subgroup. These miRNAs may function through 
repression of PIK3R1, activating the PI3K/AKT signaling 
pathway [77].
In predicting response to R-CHOP treatment, miR-21 
and miR-520 were found to be significantly dysregulated 
in at least two different studies. MiR-21 was investigated 
by four different studies. Higher levels during treatment 
were associated with inferior response in one study [80], 
decreasing posttreatment levels compared to pretreat-
ment levels with superior response in another study [65] 
and no association was found in two other studies  [58, 
81]. In the study of Cui et  al., although pretreatment 
levels were not associated with interim PET-CT status, 
the individual kinetics of mir-21 were associated with 
therapy response with decreasing values in patients that 
obtain interim PET-CT negativity in comparison to sta-
ble values in patients that remain PET-CT positive [65]. 
Two studies developed a 5- and 15-miR signature respec-
tively, associated with response to R-CHOP therapy. 
Although miR-520 was higher in both signatures, it was 
associated with response in one study and non-response 
in the other [81, 82]. A meta-analysis conducted on tissue 
samples demonstrated a significant association between 
aberrant expression of miR-155, miR-17/92 clusters, 
miR-21, miR-224 and miR-146b-5p and poor treatment 
outcomes  [83]. None of these have been significantly 
associated with treatment response in two or more stud-
ies as circulating biomarker.
Concerning prognosis in DLBCL, only cell-free miR-
21 and miR-155 have been studied in more than one 
study. The studies concerning miR-21 presented conflict-
ing results, with two studies showing higher levels as an 
independent poor prognostic factor  [57, 84], two stud-
ies demonstrating higher levels as a favorable prognos-
tic factor [53, 59], and two studies finding no significant 
association [80, 81]. In the studies with a favorable prog-
nosis, however, no multivariate analysis was performed 
and there was no association between miRNA levels and 
clinicopathological features. As a result, the significance 
of miR-21 in the prognosis of DLBCL remains uncertain. 
Of the five studies concerning miR-155, four showed an 
significant association with inferior prognosis  [60, 78, 
79, 84] and one study could not demonstrate a signifi-
cant association  [53]. MiR-155 has also been proposed 
as prognostic biomarker by several studies on DLBCL 
tissue samples, although no clear conclusion could be 
retained [77]. Zheng et al. showed that a higher level of 
miR-155 may be associated with lymphoma progression 
through modulating PD-1/PD-L1-mediated interaction 
with CD8+ T-cells of tumor microenvironment, indicat-
ing sensitivity to PD-L1 blockade [60]. Lastly, two studies 
have proposed a signature of different miRNAs as prog-
nostic predictor, independent of IPI score. Song et  al. 
developed a 5-miRNA signature, associated with median 
remission time and probability of remission [81]. Another 
4-miRNA prognostic model was significantly associated 
with relapse, as well as with worse PFS and OS [84].
Although there are some conflicting data, circulating 
miR-155 and especially miR-21 seem to hold the greatest 
potential as biomarkers for the diagnosis and subclassi-
fication of DLBCL. Regarding the prediction of therapy 
response, there is currently insufficient evidence for each 
of the proposed miRNA candidates. Concerning predic-
tion of prognosis, miR-155 has been associated with infe-
rior prognosis in several independent studies, although 
validation is needed. Lastly, several signatures that com-
bine multiple miRNAs show promising results in the 
diagnosis, prediction of therapy response and prognosis 
in DLBCL. Their potential should be further investigated 
in future studies with large sample sizes.
Extracellular vesicles
Extracellular vesicles (EVs) are a heterogeneous group of 
membrane-bounded vesicles that play an important role 
in intercellular communications. EVs are secreted by pre-
sumably all cell types and transfer a wide range of mole-
cules in their cargo including proteins, lipids, and nucleic 
acids, mirroring their cell of origin. Since their discovery 
by Wolf et  al. in 1967, their roles in normal physiology 
and in various pathologies such as cancer have been the 
subject of intensive research [85–87]. Accumulating evi-
dence shows that a heterogeneous population of cells 
may communicate via EVs, hereby mediating processes 
involved in tumorigenesis. EVs are mostly classified as 
exosomes, microvesicles (MV) or apoptotic bodies (AB) 
on the basis of their size, origin, and characteristics [88]. 
Exosomes are vesicles of endosomal origin with a size 
ranging between 40 and 150 nm. Their formation consists 
of several steps, starting with endocytic vesicle invagina-
tion on the plasma membrane, followed by the creation 
of multiple intraluminal vesicles within the endosome 
via the folding of its phospholipid bilayer, and eventually 
the fusion of this multi-vesicular body with the plasma 
membrane to release exosomes  [89, 90]. MVs are larger 
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and more heterogeneous in size, ranging from 100 nm 
to several microns, are produced as a result of bulging of 
the plasma membrane, and are shed from the cell surface 
as these blebs undergo fission upon stimulation. ABs are 
the largest particles, ranging in size from 800 to 5000 nm, 
which are produced during cellular blebbing and released 
by cells undergoing programmed cell death [91].
Exosomes are the best characterized EVs and are found 
in most biofluids, such as blood, serum, urine, cerebral 
spinal fluid, and even breast milk  [90, 92]. An abundant 
number of exosomes is released by tumor cells in com-
parison with non-tumorigenic cells [93]. They function as 
mediators of intercellular communication by transferring 
their content into other recipient cells utilizing various 
mechanisms, such as macropinocytosis, receptor or lipid 
raft mediated endocytosis, phagocytosis, or direct fusion 
with the recipient cell membrane. Exosomes have been 
shown to play a pivotal role in normal physiology and 
disease, including maintenance of cellular homeostasis, 
regulation of gene transcription, activation and modula-
tion of immune response and cancer progression [90, 92, 
94] Several studies have examined exosome-derived RNA 
as potential biomarker in DLBCL (Table 3).
Concerning diagnosis and classification, only exoso-
mal miR-451 was significantly dysregulated in at least 
two different studies  [95, 96]. MiR-451  is considered 
a tumor suppressor in different cancers. Although its 
role in DLBCL remains unclear, targets include c-MYC 
and the PI3K/AKT pathway  [97, 98]. Di et  al. identified 
an exosome-derived 5-miRNA signature that could dif-
ferentiate DLBCL patients from healthy controls, which 
included lower levels of miR-451 [96]. Using DLBCL cell 
lines, Rutherford et  al. showed that nearly one third of 
mutations in DLBCL are detectable in the EVs and that 
exosomal RNA may to reflect the cell of origin [99, 100]. 
However, to this date, there are no studies that could dis-
tinguish ABC and GCB subtypes using exosome-derived 
RNA in DLBCL patients.
Regarding therapy response, none of the biomarkers 
were examined in two different studies. Exosome-derived 
miR-99a-5p, miR-125b-5p, miR-155 and miR-451a were 
associated with therapy response in single studies  [95, 
101, 102]. Provencio et al. showed that increase of BCL-6 
mRNA in posttreatment samples compared to pretreat-
ment samples was associated with non-response to ther-
apy in a mixed population of DBLCL and FL patients. 
Furthermore, lower abundance of PTEN at time of 
diagnosis was associated with PD/R in the DLBCL sub-
group [103]. Interestingly, using DLBCL cell lines, Koch 
et  al. demonstrated a mechanism of exosome-mediated 
removal of the anthracycline doxorubicin and the anthra-
cenedione pixantrone from the cell nucleus, associated 
with decreased therapy efficiency. They showed that 
inhibition of ATP-transporter A3 (ABCA3), a protein 
involved in exosomal transport, resulted in higher sensi-
tivity to these drugs [104]. The inhibition of ABCA3 has 
also been shown to play a role in creating decreased sen-
sitivity to anti-CD20 immunotherapy through the upreg-
ulation of exosomal CD20 [105].
Concerning prognosis, higher levels of exosomal miR-
99a-5p and miR-125b-5p have been associated with infe-
rior PFS in a single studie [102]. Provencio et al. showed 
that pretreatment presence of exosome-derived AKT and 
C-MYC/BCL-6 was respectively associated with worse 
PFS and worse OS in a mixed population of responsive 
DBLCL/FL patients [103]. Since none of the biomarkers 
were examined in two different studies, no well-grounded 
conclusions can be made concerning their potential use 
in prediction of prognosis.
Exosomes have been shown to interact with the 
immune system. In  vitro uptake of DBLCL cell line-
derived exosomes in B-cells and monocytes has been 
demonstrated, while T-cells and NK cells displayed sig-
nificantly lower uptake  [106]. Exosomes contain tumor 
antigens, as well as MHC class I/II molecules, thus 
allowing direct activation of and cross-presentation to 
T-cells [107]. Zare et  al. demonstrated adverse effect of 
plasma-derived exosomes of DLBCL patients on several 
functions of NK cells [108]. Furthermore, tumor-derived 
exosomes play a role in immune invasion by secretion 
of PD-L1, thereby suppressing T-cell activation. Pog-
gio et al. showed that local blockade of exosomal PD-L1 
inhibited both local and distant tumoral growth, even in 
models resistant to anti-PD-L1 antibodies  [109]. Simi-
larly, Chen et al. showed that exosomes act as immuno-
suppressive mediators, evidenced by an upregulation 
of PD-1 and induction of apoptosis in T-cells. Further-
more, the exosomes enhanced cell proliferation, invasion, 
migration, and angiogenesis, promoting tumor growth 
in  vivo  [110]. Koch et  al. demonstrated the presence of 
“side population cells” in DLBCL, which have stemness 
properties and are capable of propagating tumor growth. 
These cells are in equilibrium with their environment, 
regulated through exosome-mediated Wingless-related 
integration site (Wnt) signaling [111].
There are several important pitfalls in the analysis of 
tumor-derived exosomes. EVs are usually classified on 
the basis of their origin. However, this classification and 
current techniques are insufficient to clearly distinguish 
each type separately. There are major differences between 
used protocols with the accuracy and the purity of prepa-
rations being highly dependent on the isolation method 
used by different laboratories, leading to discrepancies in 
the EV subpopulation obtained [112–114]. There is need 
for a standardized approach, such as proposed by the 
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(“MISEV”) guidelines, which provide protocols and 
procedures to minimize interlaboratory variation  [88]. 
Another challenge is the need to enrich for tumor-spe-
cific exosomes in order to reduce background noise from 
non-neoplastic-derived exosomes. Furthermore, studies 
in DLBCL show conflicting data whether tumor-derived 
RNA is enriched in exosomes compared to serum/
plasma  [63–65, 96, 101]. In other cancers, antibodies to 
specific surface proteins have been used to isolate the 
tumor-derived exosomes  [115]. Alternatively, bioinfor-
matic deconvolution techniques can be used to differen-
tiate tumor-derived signals from normal and neoplastic 
tissue. The use of disease-specific EV-derived markers in 
DLBCL has promising potential, but further research is 
needed in a more standardized way to allow direct com-
parison of studies.
Long non‐coding RNA
Approximately 80% of the human genome is non-coding, 
but functional. Long non-coding RNA (lncRNA) com-
prises a large and heterogeneous class of transcripts, 
arbitrarily defined as being more than 200 nucleotides in 
length [116]. They are located within intergenic, intronic, 
or antisense stretches or they overlap with protein-
coding genes  [117]. LncRNAs are expressed in differ-
ent human biofluids and are resistant to degradation by 
ribonucleases, being encapsulated inside EVs or in asso-
ciation with proteins [118]. They are involved in essential 
processes, such as chromatin remodeling, transcriptional 
regulation, and posttranscriptional modification  [119]. 
LncRNA expression profiling during B-cell develop-
ment has been performed in several studies that report 
cell type-specific expression patterns at various stages of 
B-cell development [120–122]. It has also been suggested 
that lncRNAs may play a role in the chromosome breaks 
involved in typical gene rearrangements in hematologic 
malignancies, such as BCL-6 translocation [123].
The vast majority of studies concerning dysregula-
tion of lncRNA in DLBCL have been performed on tis-
sue samples. Verma et al. examined large RNA-seq data 
sets from 116 DLBCL tissue samples and identified 2632 
novel lncRNAs, most of which were only expressed 
in malignant cells. Interestingly, more than one third 
of these lncRNAs were differently expressed between 
the GCB and ABC subtypes  [124]. Sun et  al. analyzed 
lncRNA expression profiles in three cohorts of 1043 
DLBCL patients using microarray data from the Gene 
Expression Omnibus (GEO) database. They identified 
and validated a 6-lncRNA signature that was significantly 
associated with OS, independent of conventional clini-
cal factors [125]. Zhou et al. reanalyzed the data sets and 
reported a 17-lncRNA signature, that was significantly 
associated with OS and PFS, but that was also able to 
distinguish between COO subtypes with over 90% accu-
racy [126].  Gao et  al. developed a 5-lncRNA signature 
that was differentially expressed between GCB-DLBCL 
tissue samples compared to reactive lymph nodes [127]. 
Lastly, an in silico analysis analyzed 189 lncRNAs, 
extracted from the HUGO Gene Nomenclature Com-
mittee (HGNC), and demonstrated that 83% of DLBCL 
patients showed dysregulation for the studied lncRNAs. 
Growth arrest-specific 5 (GAS5), highly up-regulated 
in liver cancer (HULC), miR-17-92a-1 cluster host gene 
(MIR17HG), and prostate cancer antigen 3 (PCA3) were 
the transcripts with the highest dysregulation score [128]. 
The potential of lncRNA expression profiling as bio-
marker in DLBCL was underlined by a meta-analysis 
conducted by Xu et al. [129].
The biological relevance of circulating ncRNAs is 
becoming increasingly clear, as their diagnostic and prog-
nostic value has been shown in several solid tumors, 
such as bladder, colorectal, esophageal, prostate, hepa-
tocellular, cervical, breast, gastric and non-small-cell 
lung cancer  [130]. The group of Isin et al. were the first 
to investigate circulating lncRNA in B-cell malignancies, 
more specifically in CLL and multiple myeloma. They 
showed a dysregulation of plasma lincRNA-p21 levels 
in CLL patients and taurine upregulated gene 1 (TUG1), 
metastasis associated lung adenocarcinoma transcript 1 
(MALAT1), HOX transcript antisense RNA (HOTAIR) 
and GAS5 in multiple myeloma patients  [131]. Wang 
et  al. are the only group to investigate circulating lncR-
NAs in DLBCL, demonstrating lower levels of p21 asso-
ciated ncRNA DNA damage activated (PANDA) and 
higher abundance of TUG1 in DLBCL patients, com-
pared to healthy controls (Table  4). Moreover, lower 
levels of PANDA were associated with inferior RFS and 
OS, independent of disease stage. They showed that 
PANDA was induced by p53 and can suppress cell pro-
liferation through inactivation of MAPK signaling path-
way. The same group analyzed the expression of lncRNAs 
in DLBCL tissue samples and found an upregulation 
of TUG1, HULC, HOTAIR, and a downregulation of 
PANDA, lincRNA-p21 and FLJ46300 in DLBCL, with tis-
sue-derived PANDA also being associated with OS [132].
Several individual lncRNA genes have been associ-
ated with DLBCL in tissue-derived specimens and 
could therefore be promising circulating biomarkers. 
LincRNA-p21 and NONHSAG026900 are shown to be 
downregulated in DLBCL tissue and are associated with 
favorable OS, as both lncRNA possibly act as tumor 
suppressors  [133, 134]. Moreover, NONHSAG026900 
was elevated in the GCB subtype compared to the 
non-GCB subtype  [134]. Leukemia-associated non-
coding IGF1R activator RNA 1 (LUNAR1), functional 
intergenic repeating RNA element (FIRRE), olfactory 
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receptor family 3 subfamily A member 4 (OR3A4) and 
retrotransposon-derived protein PEG10 (PEG10) are 
upregulated in DLBCL tissue samples and associated 
with inferior OS, acting as oncogenes  [135–138]. Peng 
et  al. demonstrated an increased HULC expression in 
DLBCL samples and higher levels were independently 
associated with inferior OS/PFS [139]. MALAT1, 
a lncRNA that is upregulated in different solid and 
hematological tumors and that has been associated 
with cancer metastasis and recurrence [131, 140, 141], 
seems to be involved in chemotherapy sensitivity in 
DLBCL cell lines by enhancing autophagy-related pro-
teins  [142]. HOTAIR is a well-known contributor to 
tumorigenesis  [143]. Two studies reported conflicting 
results regarding HOTAIR expression and prognosis in 
DLBCL  [144, 145]. The lncRNA nuclear para-speckle 
assembly transcript 1 (NEAT1) has also been associated 
with poor prognosis and may act as a competing endog-
enous RNA (ceRNA), regulating the miR-34b-5p-GLI1 
axis, stimulating the proliferation of DLBCL [146, 147]. 
Lastly, several studies have shown aberrant expres-
sion patterns of the lncRNAs small nucleolar RNA 
host gene 12 (SNHG12), SNHG14, SNHG16, TUG1, 
MALAT1 and SMAD5 antisense RNA 1 (SMAD5-AS1) 
in DLBCL samples and cell lines, indicating their use as 
potential biomarkers, although further investigation is 
warranted  [148–153]. Huang et  al. recently reviewed 
functional studies of lncRNAs in DLBCL and their 
respective role in tumor cell biology [154].
Since several promising biomarkers have been pro-
posed based on tissue samples, future research should 
focus on analyzing their expression in serum or plasma. 
Furthermore, since many lncRNAs have only been 
reported in a single study, there is a need for systematic 
validation studies that investigate multiple lncRNAs 
with well-characterized and diverse patient samples.
Circular RNA
Circular RNAs (circRNAs) are a recently discovered sub-
class of large ncRNA, widely expressed in mammalian 
cells. They originate from a host gene and are formed 
through a backsplicing event, linking the 3′ end of an 
exon to the 5′ end of the same or an upstream exon [155]. 
CircRNAs may function as direct or indirect regulators 
of host gene expression at the transcriptional level, as 
protein scaffolds, as sponges of miRNAs, as regulators of 
protein translation, or under certain circumstances even 
as templates for translation  [156, 157]. Many circRNAs 
are highly evolutionary conserved, resistant to exonu-
cleases due to their closed structure, and thus more sta-
ble than linear non-coding RNAs such as miRNA and 
lncRNA, which highlights their potential to serve as cell-
free biomarkers [158, 159].
 No studies have yet examined their role during normal 
B-cell development and differentiation. However, specific 
circRNA signatures seem to be characteristic for B-cells 
compared to T-cells and progenitors [160]. Furthermore, 
circRNAs have been shown to play a role in the patho-
genesis of cancer and circRNA expression profiles can 
differentiate between different B-cell malignancies  [161, 
162]. Several circRNAs are rich in miRNA-binding sites 
and can act as highly efficient ceRNA in cells by com-
peting in binding to miRNAs, facilitating tumorigenesis. 
Using DLBCL cell lines, Chen et  al. showed that circ-
CFL1 targets the miR-107 target gene HMGB1, resulting 
in an increased expression of HMGB1, thereby upregu-
lating the phosphorylation levels of p-AKT, p-ERK, and 
p-STAT3, which are involved in signaling pathways that 
control cell proliferation and migration  [163]. Research 
in Burkitt lymphoma demonstrated a MYC-miR-150-
ZDHHC11/B-MYB network, in which high levels of 
MYC repress miR-150, which leads to derepression of 
MYB, ZDHHC11 and ZDHHC11B, and promotes pro-
liferation. Moreover, upregulation of the circRNAs 
Table 4 Cell-free lncRNA in DLBCL
DLBCL diffuse large B-cell lymphoma, lncRNA long non-coding RNA, NS not significant, OS overall survival, RFS relapse-free survival, RT-qPCR reverse-transcription 
quantitative polymerase chain reaction
References Method Sample lncRNA Level Result
Diagnosis









Lower level in DLBCL
Higher level in DLBCL
No difference
Prognosis
Wang et al. [132] RT-qPCR serum 68 DLBCL
68 controls
PANDA Down Lower level was associated with worse 
RFS and OS, independent of disease 
stage
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ZDHHC11 and ZDHHC11B increases expression of the 
MYC target MYB proto-oncogene through a mechanism 
in which they could act as ceRNAs for miR-150  [164]. 
Yang et  al. showed that circRNA circAmotl1 promotes 
nuclear translocation of MYC, as well as upregulation 
of MYC targets and, therefore, plays a possible role in 
lymphomagenesis  [165]. Since MYC upregulation is fre-
quently observed in DLBCL, these circRNAs may be of 
importance in further research. Interestingly, chromo-
somal translocations have been described producing 
fusion-circRNAs [166].
A recent study by Hu et  al. is the first to explore the 
potential of circRNA as biomarker in DLBCL. They dem-
onstrated that circAPC was significantly downregulated 
in DLBCL tissues and associated with aggressive clini-
cal features and poor prognosis. CircAPC elevates the 
expression of the host gene adenomatous polyposis coli 
(APC), thereby inactivating canonical Wnt/β-catenin 
signaling and restraining DLBCL growth. Moreover, 
circAPC levels in plasma sample were also significantly 
lower in DLBCL patients and could serve as a potential 
diagnostic noninvasive marker [167] (Table  5).  These 
results have to be confirmed in future studies.
Although circRNAs are increasingly being investigated 
in cancer research, there are several challenges. Firstly, 
there is a need for a common standard in reporting and 
naming circRNAs. Secondly, circRNAs lack poly(A) tails, 
which are often relied on for the purification step in order 
to remove ribosomal RNA during sequencing. Substan-
tial methodological difficulties like template switching 
and rolling circle amplification during reverse transcrip-
tion, as well as amplification bias during PCR have been 
formulated as well  [161, 168]. Moreover, results depend 
highly on the strategy of library preparation and choice 
of one of the many available bioinformatic algorithms. 
Some of these challenges are, however, increasingly being 
encountered using newer techniques, such as the Nanop-
ore RNA sequencing or the nCounter platform, showing 
promising potential to further explore the use of circR-
NAs as biomarkers in malignant diseases [161, 162].
Tumor‐educated platelets
Blood platelets are small, circulating cell fragments that 
originate from megakaryocytes. They are best known for 
their role in hemostasis and initiation of wound healing. 
Platelets as part of the microenvironment, however, are 
also increasingly recognized to be involved in tumoral 
processes in which they stimulate proliferation, facili-
tate metastasis, and induce phenotypic changes in cancer 
cells. Because of their anucleate status, the majority of 
transcriptional production of RNA occurs in the mega-
karyocyte. Therefore, the RNA profile in platelets reflects 
the transcriptional status of megakaryocytes, as well as 
the bone marrow or other local environmental signals 
involved at the time of platelet production [29]. Increas-
ing evidence shows that platelets can also be ‘educated’ 
by tumors (tumor-educated platelets; TEPs) by altering 
the platelets RNA profile, mainly through the process of 
specific pre-mRNA splicing and to lesser extent by inges-
tion of tumor-derived circulating mRNA [27–31]. These 
changes may be induced by cancer cells or by other exter-
nal stimuli from the microenvironment  [30]. Through 
these mechanisms, platelets have a rich repertoire of 
RNAs, including mRNAs, structural and catalytic RNAs 
(ribosomal RNA, transfer RNA, and small nucleolar 
RNA), and regulatory RNAs (microRNA and long non-
coding RNA) [28, 29, 31, 169].
Best et al. showed that mRNA sequencing of TEPs dis-
criminated metastatic cancer cases from healthy controls 
with 96% accuracy and localized primary tumors with 
71% accuracy across six different solid tumor types. The 
tumor-specific educational programs in TEPs were pre-
dominantly influenced by tumor type, and to a lesser 
extent, by tumor progression and metastasis. The sig-
natures showed widespread correlation with cancer tis-
sues and a negative correlation with RNAs implicated in 
RNA translation, T-cell immunity, and interleukin sign-
aling, the latter implying an important role in regulating 
the immune response in the tumoral microenvironment. 
Lastly, they identified several tumor-derived genetic 
alterations in TEPs  [28]. In a recent study, the spliced 
RNA profile of TEPs was able to differentiate glioblas-
toma patients from healthy controls with an accuracy of 
95%. Moreover, individual TEP tumor scores represented 
tumor behavior and were able to distinguish false posi-
tive progression from true progression with an accuracy 
of 85% [170]. These findings suggest that TEPs contain a 
unique source of functional and genomic tumoral infor-
mation, obtained by a mechanism distinct from that 
which generates circulating-free DNA and RNA, which 
Table 5 Cell-free circRNA in DLBCL
DLBCL diffuse large B-cell lymphoma, circRNA circular RNA, RT-qPCR reverse-transcription quantitative polymerase chain reaction
References Method Sample circRNA Level Result
Diagnosis
Hu et al. [167] RT-qPCR plasma 27 DLBCL
16 controls
Circ-APC Down Lower level in DLBCL
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may implicate an complementary role in personalized 
non-invasive cancer management. At this time, no stud-
ies of TEPs have been performed in DLBCL, although 
this could produce a valuable contribution to the research 
field of liquid biopsy.
Conclusion and future perspectives
In recent years, major progress has been made in iden-
tifying cell-free RNA biomarkers for the diagnosis, dis-
ease subtype classification, prediction of treatment 
response or prognosis in DLBCL. The vast majority of 
research has been performed in circulating (vesicle-
encapsulated) miRNA, where some have shown consist-
ent changes in several independent studies and could be 
further explored as diagnostic and prognostic biomark-
ers. While promising results were reported for differ-
ent solid tumors, the use of cell-free mRNA, lncRNA, 
circRNA, and TEP-derived RNA has only sparsely been 
investigated in DLBCL and further studies are needed to 
analyze their potential.
There are no studies investigating the mutational pro-
file, editing and alternative splicing of circulating RNA 
in DLBCL patients. We believe that further research 
should focus on other aspects beyond abundance, as this 
can provide valuable information on the cell of origin, as 
well as on the function of circulating RNAs. In the same 
vein, a promising future perspective is combining cell-
free DNA and RNA, as well as other cellular molecules, 
in an multiomics approach. This could have far-reaching 
impact and push the field forward in identifying minimal 
invasive, disease-specific biomarkers that can be rou-
tinely implemented in clinical practice.
Concerning methodology, the development of unique 
circulating signatures in DLBCL with high specificity 
and sensitivity requires a standardized and consist-
ent approach that must be applied during the whole 
research process, from blood collection to plasma/
serum preparation, handling, and banking to extrac-
tion and quantification. Furthermore, defining and 
establishing validated reference sample sets is neces-
sary. In addition, the experimental design of the study 
must be clear, including an adequate sample size rela-
tive to the objectives and possible variabilities, as well 
as validation of the results in an independent cohort, 
which is not included in most studies. Concerning the 
use of EV in biomarker development, a standardized 
workable isolation method is needed to ensure that the 
same term covers the same load in different research. 
Future progress in characterizing the content of lipid 
vesicles and unraveling the processes involved in their 
formation and function will contribute to a better 
understanding of their potential use as biomarkers in 
malignant diseases. Lastly, it would be important to see 
how cell-free biomarker candidates would perform in 
large prospective clinical trials.
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host gene 14/small nucleolar RNA host gene 16; SOCS: Suppressor of cytokine 
signaling; STAT3: Signal transducer and activator of transcription 3; TEP: Tumor-
educated platelet; TUG1: Taurine upregulated gene 1; Wnt: Wingless-related 
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